Heron Therapeutics, Inc. (HRTX) P/E Ratio History
Deep ValueTrading at -3.6x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 1997–2006
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Heron Therapeutics, Inc. (HRTX) trades at a price-to-earnings ratio of -3.6x, with a stock price of $0.43 and trailing twelve-month earnings per share of $-0.16.
The current P/E is 106% below its 5-year average of 60.9x. Over the past five years, HRTX's P/E has ranged from a low of 1.0x to a high of 495.6x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, HRTX trades at a 116% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, HRTX trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HRTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HRTX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
HRTX P/E vs Peers
Drug Delivery Technology Platforms peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $893M | 141.9 | - | +107% | |
| $2B | 6.9Lowest | 0.66Best | +817%Best | |
| $2B | 12.3 | - | +8% | |
| $90B | 19.4 | - | +49% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
HRTX Historical P/E Data (1997–2006)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2006 Q2 | Jun 30 2006 | $140.00 | $32.53 | 4.3x | -93% |
| FY2006 Q1 | Mar 31 2006 | $160.00 | $38.94 | 4.1x | -93% |
| FY2001 Q2 | Jun 30 2001 | $240.00 | $150.94 | 1.6x | -97% |
| FY2001 Q1 | Mar 31 2001 | $165.00 | $153.15 | 1.1x | -98% |
| FY2000 Q4 | Dec 31 2000 | $190.00 | $160.79 | 1.2x | -98% |
| FY2000 Q3 | Sep 30 2000 | $170.00 | $172.65 | 1.0x | -98% |
| FY2000 Q2 | Jun 30 2000 | $302.50 | $15.85 | 19.1x | -69% |
| FY2000 Q1 | Mar 31 2000 | $400.00 | $20.27 | 19.7x | -68% |
| FY1999 Q4 | Dec 31 1999 | $275.00 | $23.47 | 11.7x | -81% |
| FY1999 Q3 | - | $330.00 | $22.29 | 14.8x | -76% |
| FY1999 Q2 | Jun 30 1999 | $560.00 | $22.29 | 25.1x | -59% |
| FY1999 Q1 | Mar 31 1999 | $350.00 | $23.58 | 14.8x | -76% |
| FY1998 Q4 | - | $430.00 | $17.18 | 25.0x | -59% |
| FY1998 Q3 | Sep 30 1998 | $435.00 | $12.40 | 35.1x | -42% |
| FY1998 Q2 | - | $560.00 | $1.13 | 495.6x | +714% |
| FY1997 Q4 | Dec 31 1997 | $530.00 | $1.77 | 299.4x | +392% |
Average P/E for displayed period: 60.9x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
29+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
HRTX — Frequently Asked Questions
Quick answers to the most common questions about buying HRTX stock.
What is HRTX's P/E ratio?
Heron Therapeutics, Inc. (HRTX) trailing twelve-month P/E ratio is -3.6x, based on TTM diluted EPS of $-0.16. The 5-year average P/E is 60.9x and the historical range spans 1.0x to 495.6x.
Is HRTX stock overvalued or undervalued?
HRTX trades at -3.6x P/E, below its 5-year average of 60.9x. At the 0th percentile of its historical range (1.0x–495.6x), the stock is priced at a discount to its own history.
Is HRTX stock expensive?
No, HRTX is not expensive on a historical basis. The current P/E of -3.6x is below the 5-year average of 60.9x and sits at the 0th percentile of its valuation range.
What is HRTX's historical P/E range?
Over the past 5 years, HRTX's P/E ratio has ranged from 1.0x to 495.6x, with a median of 14.8x and an average of 60.9x. The current P/E of -3.6x places the stock at the 0th percentile of this range. Full historical data spans 1997–2006.
How does HRTX's P/E compare to the S&P 500?
HRTX trades at -3.6x P/E versus the S&P 500 median of 24.3x. The 115% discount to the market suggests lower growth expectations or perceived higher risk.
How does HRTX's valuation compare to Healthcare peers?
Heron Therapeutics, Inc. P/E of -3.6x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is HRTX's PEG ratio?
HRTX PEG ratio is N/A, based on a P/E of -3.6x and EPS growth of -34.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is HRTX's earnings yield?
HRTX earnings yield is N/A, the inverse of its -3.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.